H
HALOZYME THERAPEUTICS INC
NASDAQ: HALO (Halozyme Therapeutics, Inc.)
Last update: 11 hours ago76.90
-0.63 (-0.81%)
| Previous Close | 77.53 |
| Open | 77.04 |
| Volume | 1,073,964 |
| Avg. Volume (3M) | 2,211,232 |
| Market Cap | 8,994,685,952 |
| Price / Earnings (TTM) | 17.60 |
| Price / Earnings (Forward) | 9.23 |
| Price / Sales | 8.21 |
| Price / Book | 26.64 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | 44.76% |
| Operating Margin (TTM) | 53.44% |
| Diluted EPS (TTM) | 3.76 |
| Quarterly Revenue Growth (YOY) | 35.20% |
| Quarterly Earnings Growth (YOY) | 53.70% |
| Total Debt/Equity (MRQ) | 318.67% |
| Current Ratio (MRQ) | 8.39 |
| Operating Cash Flow (TTM) | 503.86 M |
| Levered Free Cash Flow (TTM) | 402.43 M |
| Return on Assets (TTM) | 18.50% |
| Return on Equity (TTM) | 147.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Halozyme Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.6
| Analyst Consensus | -1.5 |
| Insider Activity | -5.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.60 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 101.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Snyder Capital Management L P | 30 Jun 2025 | 3,397,697 |
| Congress Asset Management Co | 30 Jun 2025 | 1,835,411 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (Morgan Stanley, 4.03%) | Buy |
| Median | 76.50 (-0.52%) | |
| Low | 63.00 (JP Morgan, -18.08%) | Hold |
| Average | 74.00 (-3.77%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 63.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 18 Aug 2025 | 80.00 (4.03%) | Buy | 68.96 |
| 06 Aug 2025 | 75.00 (-2.47%) | Buy | 62.32 | |
| JP Morgan | 07 Aug 2025 | 63.00 (-18.08%) | Hold | 62.10 |
| 16 Jul 2025 | 60.00 (-21.98%) | Hold | 58.01 | |
| HC Wainwright & Co. | 06 Aug 2025 | 75.00 (-2.47%) | Buy | 62.32 |
| JMP Securities | 06 Aug 2025 | 78.00 (1.43%) | Buy | 62.32 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CONNAUGHTON BERNADETTE | - | 73.34 | -4,000 | -293,360 |
| TORLEY HELEN | - | 73.85 | -60,000 | -4,431,200 |
| Aggregate Net Quantity | -64,000 | |||
| Aggregate Net Value ($) | -4,724,560 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 73.73 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TORLEY HELEN | Officer | 04 Sep 2025 | Automatic sell (-) | 20,000 | 73.40 | 1,468,000 |
| TORLEY HELEN | Officer | 04 Sep 2025 | Option execute | 20,000 | - | - |
| TORLEY HELEN | Officer | 03 Sep 2025 | Automatic sell (-) | 20,000 | 74.82 | 1,496,400 |
| TORLEY HELEN | Officer | 03 Sep 2025 | Option execute | 20,000 | - | - |
| CONNAUGHTON BERNADETTE | Director | 02 Sep 2025 | Automatic sell (-) | 4,000 | 73.34 | 293,360 |
| TORLEY HELEN | Officer | 02 Sep 2025 | Automatic sell (-) | 20,000 | 73.34 | 1,466,800 |
| TORLEY HELEN | Officer | 02 Sep 2025 | Option execute | 20,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Halozyme to Participate at Upcoming Investor Conferences |
| 05 Aug 2025 | Announcement | HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS |
| 23 Jul 2025 | Announcement | European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma |
| 22 Jul 2025 | Announcement | Halozyme to Report Second Quarter 2025 Financial and Operating Results |
| 30 Jun 2025 | Announcement | Halozyme Therapeutics Added to Russell 1000® Index |
| 20 Jun 2025 | Announcement | Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |